Dexcom Inc

DexCom maintains a robust liquidity position with $1.105 billion in cash and equivalents and a current ratio of 1.73. The balance sheet shows total assets of $6.455 billion against total liabilities of $3.834 billion, resulting in total equity of $2.621 billion. The company carries $1.243 billion in long-term senior convertible notes, which contributes to a reported debt-to-equity ratio of 0.0 in the valuation snapshot, likely due to the classification of these convertible instruments or specific accounting treatments for the metric. Free cash flow for the period reached $633.5 million, demonstrating strong cash generation capabilities relative to capital expenditures of $161.3 million.

Profitability metrics indicate high returns on capital, with a return on equity of 31.9% and return on assets of 12.96%. The company reported net income of $448.6 million on revenue of $2.500 billion, yielding a net margin of approximately 17.9%. Operating income stood at $573.6 million, reflecting an operating margin of roughly 22.9%. These returns are supported by a gross profit of $1.580 billion, indicating a gross margin of approximately 63.2%.

Revenue generation is driven by the sale of continuous glucose monitoring systems, with significant exposure to the United States market as indicated by the segmentation of sales channels through intermediaries and direct-to-consumer models. The company also reports non-US revenue, though specific geographic breakdowns are not detailed in the provided snapshot. The business model relies on recurring revenue from sensor replacements, supported by partnerships for integration with insulin delivery devices.

Growth trajectory is evidenced by the increase in net income from $285.2 million in the first half of 2025 to $448.6 million in the first half of 2026. Operating cash flow also expanded significantly from $486.8 million to $794.8 million year-over-year. The company has been active in share repurchases, spending $603.6 million on treasury stock purchases in the first half of 2026, compared to no repurchases in the same period of 2025.

Risk assessment highlights high dilution risk, driven by a diluted share count of 391.8 million shares compared to 377.4 million basic shares. This difference suggests the potential impact of convertible notes and equity-based compensation on share count. Liquidity risk is assessed as low, supported by the strong cash position and current ratio. Key flags include the moderate gap between basic and diluted shares and source documents mentioning dilution or offering risk.

Recent events include the filing of an 8-K report with material items under Item 2.02, indicating significant corporate developments or financial results announcements. Analyst sentiment remains positive, with a mean recommendation of 1.70 (where 1 is strong buy) and a mean price target of $92.46, suggesting upside from the current market price of $83.45. The company continues to invest in research and development, with expenses reported in the cash flow statements, supporting its innovation pipeline.

Revenue $2.50B; Operating income $573.6M.

• ▍Revenue $2.50B
• ▍Operating income $573.6M
• ▍Net margin 17.9%

Revenue $1.19B; Operating income $255.3M.

• ▍Revenue $1.19B
• ▍Operating income $255.3M
• ▍Net margin 16.7%

Revenue $4.66B; Operating income $911.8M.

• ▍Revenue $4.66B
• ▍Operating income $911.8M
• ▍Net margin 17.9%

Revenue $4.03B; Operating income $600.0M.

• ▍Revenue $4.03B
• ▍Operating income $600.0M
• ▍Net margin 14.3%

Revenue $4.03B; Operating income $600.0M.

• ▍Revenue $4.03B
• ▍Operating income $600.0M
• ▍Net margin 14.3%

Revenue $3.62B; Operating income $597.7M.

• ▍Revenue $3.62B
• ▍Operating income $597.7M
• ▍Net margin 14.9%

Revenue $3.62B; Operating income $597.7M.

• ▍Revenue $3.62B
• ▍Operating income $597.7M
• ▍Net margin 14.9%